SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-042223
Filing Date
2023-12-20
Accepted
2023-12-20 16:01:36
Documents
12
Period of Report
2023-12-20
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20231220.htm   iXBRL 8-K 41543
  Complete submission text file 0001628280-23-042223.txt   166552

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20231220.xsd EX-101.SCH 1969
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20231220_lab.xml EX-101.LAB 24183
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20231220_pre.xml EX-101.PRE 12576
6 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20231220_htm.xml XML 2625
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 231501336
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)